Jacobs Levy Equity Management Inc. Has $693,000 Stock Holdings in Accuray Incorporated (NASDAQ:ARAY)

Jacobs Levy Equity Management Inc. increased its holdings in shares of Accuray Incorporated (NASDAQ:ARAY) by 143.1% in the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 384,944 shares of the medical equipment provider’s stock after purchasing an additional 226,602 shares during the quarter. Jacobs Levy Equity Management Inc.’s holdings in Accuray were worth $693,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently bought and sold shares of the stock. BNP Paribas Financial Markets increased its position in shares of Accuray by 1,650.6% during the third quarter. BNP Paribas Financial Markets now owns 146,384 shares of the medical equipment provider’s stock worth $263,000 after acquiring an additional 138,022 shares in the last quarter. FMR LLC boosted its stake in Accuray by 27.2% in the 3rd quarter. FMR LLC now owns 582,591 shares of the medical equipment provider’s stock worth $1,049,000 after purchasing an additional 124,459 shares during the period. Dynamic Technology Lab Private Ltd bought a new position in Accuray during the 3rd quarter worth about $231,000. Foundry Partners LLC raised its stake in shares of Accuray by 51.3% in the 3rd quarter. Foundry Partners LLC now owns 2,187,160 shares of the medical equipment provider’s stock valued at $3,937,000 after purchasing an additional 741,900 shares during the period. Finally, Intech Investment Management LLC bought a new stake in shares of Accuray in the third quarter valued at about $41,000. 64.08% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Separately, StockNews.com lowered Accuray from a “buy” rating to a “hold” rating in a research report on Friday, November 15th.

Accuray Stock Performance

Shares of ARAY opened at $2.09 on Tuesday. The company has a current ratio of 1.63, a quick ratio of 0.87 and a debt-to-equity ratio of 3.59. Accuray Incorporated has a 12 month low of $1.40 and a 12 month high of $3.05. The firm has a fifty day simple moving average of $1.89 and a 200 day simple moving average of $1.87. The stock has a market capitalization of $210.19 million, a price-to-earnings ratio of -12.29 and a beta of 1.44.

Accuray (NASDAQ:ARAY) last posted its quarterly earnings data on Wednesday, November 6th. The medical equipment provider reported ($0.04) EPS for the quarter, hitting analysts’ consensus estimates of ($0.04). The company had revenue of $101.55 million during the quarter, compared to the consensus estimate of $98.10 million. Accuray had a negative net margin of 3.72% and a negative return on equity of 36.93%. During the same period in the prior year, the business posted ($0.03) EPS. Research analysts forecast that Accuray Incorporated will post 0.01 EPS for the current fiscal year.

Accuray Company Profile

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.